{"summary":"Resourceful life sciences professional with experience in sales and marketing and project management","lastName":"P.","objectUrn":"urn:li:member:138092977","geoRegion":"Singapore, Singapore","fullName":"Meghan Han P.","firstName":"Meghan Han","currentPositions":[{"companyName":"Merck Life Science","description":"Supporting our holistic offerings in emerging therapy modalities such as antibody conjugates (ADC), cell & gene therapies and mRNA. Engage customers holistically by understanding their process development pain points and providing modality based application consultancy to accelerate therapy development","title":"Technical Application Expert (Novel Modalities)- SEATW & ANZ","companyUrnResolutionResult":{"employeeCountRange":"10001+","headquarters":{"country":"Germany","city":"Darmstadt","postalCode":"64293","line1":"Frankfurter Stra\u00dfe 250"},"website":"http:\/\/www.sigmaaldrich.com","flagshipCompanyUrl":"https:\/\/www.linkedin.com\/company\/merck-life-science\/","industry":"Biotechnology Research"},"companyUrn":"urn:li:fs_salesCompany:16233341","tenureAtCompany":{"numYears":2,"numMonths":4},"startedOn":{"month":1,"year":2024}}],"entityUrn":"urn:li:fs_salesProfile:(ACwAAAg7IbEBrI3ER2OVDDD3eaq9hAXvzazH_J0,NAME_SEARCH,pbfx)","profilePictureDisplayImage":{"artifacts":[{"width":100,"fileIdentifyingUrlPathSegment":"100_100\/0\/1711850362880?e=1723075200&v=beta&t=EmTPa1-IJOhdpcrFneh8Y09TM3Sj-_mp6qV2Ar70qPY","height":100},{"width":200,"fileIdentifyingUrlPathSegment":"200_200\/0\/1711850362880?e=1723075200&v=beta&t=Cs2iqGn6moadTcHtwUzzf98-8A1J50QkU5HpH1yzjw0","height":200},{"width":400,"fileIdentifyingUrlPathSegment":"400_400\/0\/1711850362880?e=1723075200&v=beta&t=s5iDe6sHBEUmQMoymKYA3GXe9-qfywXxQpSc03sjahQ","height":400},{"width":800,"fileIdentifyingUrlPathSegment":"800_800\/0\/1711850362880?e=1723075200&v=beta&t=BIjBBowCIUmhueZu41myrEKgmyzfZZ-7cIDer0vxsZo","height":800}],"rootUrl":"https:\/\/media.licdn.com\/dms\/image\/D5603AQG1bOmtQNaJkQ\/profile-displayphoto-shrink_"},"projects":[],"contactInfo":{},"industry":"Pharmaceutical Manufacturing","educations":[{"degree":" LLP Startup Acceleration Programme, NUS Enterprise ","schoolUrn":"urn:li:fs_salesSchool:5524","eduId":579428728,"school":"urn:li:fs_salesSchool:5524","fieldsOfStudy":["Commercialising Technological Innovation"],"schoolName":"National University of Singapore"},{"degree":"Bachelor's Degree","schoolUrn":"urn:li:fs_salesSchool:5524","eduId":103563745,"school":"urn:li:fs_salesSchool:5524","fieldsOfStudy":["Bioengineering"],"schoolName":"National University of Singapore"},{"school":"urn:li:fs_salesSchool:941061","degree":"A-level","schoolName":"Raffles Institution","schoolUrn":"urn:li:fs_salesSchool:941061","eduId":103565238},{"school":"urn:li:fs_salesSchool:14459103","degree":"O level ","schoolName":"Chung Cheng High School (Main)","schoolUrn":"urn:li:fs_salesSchool:14459103","eduId":768559093}],"skills":[{"numOfEndorsement":2,"name":"Business Development"},{"numOfEndorsement":1,"name":"Product Marketing"},{"numOfEndorsement":1,"name":"Competitive Intelligence"},{"numOfEndorsement":0,"name":"Product Management"},{"numOfEndorsement":0,"name":"Teamwork"},{"numOfEndorsement":0,"name":"Distributor Management"},{"numOfEndorsement":0,"name":"Biotechnology Industry"},{"numOfEndorsement":0,"name":"Lifescience industry"}],"numOfConnections":1062,"patents":[],"headline":"Life science | sales and marketing","courses":[],"certifications":[{"authority":"Ngee Ann Polytechnic","name":"ICH Q10 Quality Risk Management in the Pharmaceutical Industry","startedOn":{"month":8,"year":2019}}],"memberBadges":{"premium":false,"openLink":true,"jobSeeker":false},"flagshipProfileUrl":"https:\/\/www.linkedin.com\/in\/meghan-han-peng","organizations":[],"location":"Singapore, Singapore","publications":[],"positions":null,"posts":[{"createdAt":1717227960000,"insightId":"eee5fb43-9819-4fab-9eb2-1bad228b3d12","activityUnion":{"postActivity":{"contentSummaryUnion":{"ingestedContentSummary":{"description":"Thursday, June 06, 2024 at 4:00 PM Central European Summer Time.","fullText":"Thursday, June 06, 2024 at 4:00 PM Central European Summer Time.","resolvedUrl":"https:\/\/event.on24.com\/wcc\/r\/4571609\/82432E1DBE087E6E535CDD3F3A22BF7E?partnerref=linkedInShareFromReg&ms=1717227872726","title":"Make More Lentivirus and Make it Right the First Time","sourceDomain":"event.on24.com"}},"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":5},{"type":"PRAISE","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:activity:7202576300035760128","threadUrn":"urn:li:activity:7202576300035760128","reactionsCount":6,"commentsCount":0,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7202576299356270592","message":{"attributes":[{"start":110,"length":11,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:scientists"}}},{"start":122,"length":8,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:webinar"}}},{"start":131,"length":11,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:lentivirus"}}},{"start":143,"length":10,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:community"}}}],"text":"Dear Lenti-virus scientists community,\n\nExciting news for you! Come and join this webinar to discover more. \n\n#Scientists #Webinar #Lentivirus #Community \ud83d\ude03 "},"entityUrn":"urn:li:share:7202576299356270592"}}},{"createdAt":1715309100000,"insightId":"8c909870-381a-49d4-8cf7-edab35ee96b4","activityUnion":{"postActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":12}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:activity:7194527925621174272","threadUrn":"urn:li:activity:7194527925621174272","reactionsCount":12,"commentsCount":0,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7194527925168214017","message":{"attributes":[],"text":"Dear friends from mRNA space, we are organizing a webinar featuring speakers from mRNA vaccine developers from WHO MPP mRNA technology transfer partners like Afrigen, PT BioFarma, Incepta. Sign-up to find out more if it is something you may interest :)"},"rootActivity":{"contentSummaryUnion":{"ingestedContentSummary":{"image":{"attributes":[{"originalImageUrl":"https:\/\/media.licdn.com\/dms\/image\/D5610AQHa2igb8oxedg\/image-shrink_1280\/0\/1715179373053?e=1717977600&v=beta&t=zZxjnLUZhyVeD2bmFs-IHRX1EiyjbYaJ1m--X7jkOmg","sourceType":"URL","imageUrl":"https:\/\/media.licdn.com\/dms\/image\/D5610AQHa2igb8oxedg\/image-shrink_1280\/0\/1715179373053?e=1717977600&v=beta&t=zZxjnLUZhyVeD2bmFs-IHRX1EiyjbYaJ1m--X7jkOmg"}]},"resolvedUrl":"https:\/\/bit.ly\/3JYoLJb","title":"e-Seminar : A Unique Dialogue on mRNA Technology Transfer Hub Program and Best Practices in Analytics Development"}},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7193983704115920896","message":{"attributes":[{"start":1930,"length":5,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:mrna"}}},{"start":1936,"length":19,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:technologytransfer"}}},{"start":1956,"length":4,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:hub"}}},{"start":1961,"length":19,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:platformtechnology"}}},{"start":1981,"length":9,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:eseminar"}}},{"start":1991,"length":12,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:merckevents"}}},{"start":2004,"length":12,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:registernow"}}},{"start":2017,"length":15,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:specialedition"}}},{"start":2033,"length":8,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:afrigen"}}},{"start":2042,"length":4,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:usp"}}},{"start":2047,"length":11,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:biogeneric"}}},{"start":2059,"length":10,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:sinergium"}}},{"start":2070,"length":9,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:biofarma"}}},{"start":2080,"length":8,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:incepta"}}}],"text":"Dear Friends on LinkedIn,\n\nYou are cordially invited to our upcoming eSeminar, where we will delve into the pivotal topic of technology transfer, with a primary focus on mRNA platform development. We aim to provide a real-world case study on establishing the process platform from scratch, along with technical case studies and practical guidance on the latest analytical procedure guidelines. This seminar is designed to help you gain insights into mRNA process development and prepare for CMC filing.\n\n====================\n\nSince the groundbreaking realization of mRNA technology in human vaccines, this platform has emerged as a powerful tool in the fight against pandemics, rare diseases, and personalized medicines. It also holds the promise of improving equitable access to vaccines and medicines in regions in need. Notably, the WHO mRNA Technology Transfer has been a highlight among many initiatives in this domain.\n\nWe are honored to collaborate with our esteemed speakers and facilitate a unique dialogue for a one-of-a-kind technology transfer program aimed at establishing sustainable local mRNA platform technology capabilities. The seminar will also cover the most recently released mRNA analytical guidelines and best practices for the evolving regulatory landscape. Our panel discussion will foster a deep understanding of the strengths and challenges through technology transfer. \n\nThe dialogue will involve the mRNA platform originator (Afrigen, the Hub and Center of Excellence), platform receiving parties (Biogeneric Pharma, Sinergium Biotech, PT Biofarma, Incepta Vaccine), and the leading authority in establishing mRNA analytical guidelines - the US Pharmacopeia (USP).\n\n=====================\nWe hope to see you online on June 4th!\n\n=======================\n\ud83d\udce2 Upcoming event!\n\ud83d\udca1 Don't miss our eSeminar on June 4, 2024, at 6:00 PM SGT. \n=======================\nRegister now to gain valuable insights! \ud83d\udc4d\n\n#mRNA #TechnologyTransfer #Hub #PlatformTechnology #eSeminar #MerckEvents #RegisterNow #SpecialEdition #Afrigen #USP #Biogeneric #Sinergium #Biofarma #Incepta"},"entityUrn":"urn:li:share:7193983704115920896"},"entityUrn":"urn:li:share:7194527925168214017"}}},{"createdAt":1711690920000,"insightId":"b894de2e-3561-4672-8715-efa97f3c3cf7","activityUnion":{"postActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":5},{"type":"PRAISE","count":2}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:activity:7179352253043003392","threadUrn":"urn:li:activity:7179352253043003392","reactionsCount":7,"commentsCount":0,"canComment":true},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7179352252615155712","message":{"attributes":[],"text":"That is great news for the patients. Pricing point looks unrealistic against the cost of manufacturing."},"rootActivity":{"contentSummaryUnion":{"ingestedContentSummary":{"image":{"attributes":[{"originalImageUrl":"https:\/\/media.licdn.com\/dms\/image\/sync\/D4E27AQFTj2003lVK0A\/articleshare-shrink_800\/0\/1712241749955?e=1717977600&v=beta&t=JnWziQ5t5cqVpN1u0NVqzE0bvCwHdJ9hTOYoZIYh1gk","sourceType":"URL","imageUrl":"https:\/\/media.licdn.com\/dms\/image\/sync\/D4E27AQFTj2003lVK0A\/articleshare-shrink_800\/0\/1712241749955?e=1717977600&v=beta&t=JnWziQ5t5cqVpN1u0NVqzE0bvCwHdJ9hTOYoZIYh1gk"}]},"publishedAt":1710979200000,"description":"The treatment, called NexCAR19, raises hopes that this transformative class of medicine will become more readily available in low- and middle-income countries.","fullText":"A small Indian biotechnology company is producing a home-grown version of a cutting-edge cancer treatment known as chimeric antigen receptor (CAR) T-cell therapy that was pioneered in the United States. CAR-T therapies are used mainly to treat blood cancers and have burgeoned in the past few years. The Indian CAR-T therapy costs one-tenth that of comparable commercial products available globally. doi: https:\/\/doi.org\/10.1038\/d41586-024-00809-y","resolvedUrl":"https:\/\/www.nature.com\/articles\/d41586-024-00809-y","title":"Cutting-edge CAR-T cancer therapy is now made in India \u2014 at one-tenth the cost","sourceDomain":"nature.com"}},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:share:7178932512956592128","message":{"attributes":[{"start":10,"length":10,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:immunoact"}}},{"start":21,"length":9,"value":{"com.linkedin.common.HashtagAttributedEntity":{"hashtag":"urn:li:hashtag:immuneel"}}},{"start":177,"length":24,"value":{"com.linkedin.common.HyperlinkAttributedEntity":{"url":"https:\/\/lnkd.in\/gi4DGh9e"}}}],"text":"Thank you #immunoACT #immuneel for paving the way for cheaper and very accessible CAR-T treatments. We know where to go now for CAR-T treatments against lymphoma and leukemia!\n\nhttps:\/\/lnkd.in\/gi4DGh9e"},"entityUrn":"urn:li:share:7178932512956592128"},"entityUrn":"urn:li:share:7179352252615155712"}}},{"createdAt":1709873580000,"insightId":"19eb87d8-c411-4293-8e2c-ed1bf79b112e","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7171520564895887360,7171729603554660353)","threadUrn":"urn:li:ugcPost:7171520564895887360","reactionsCount":0,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"Hmm... thought provoking..."},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7171520564895887360"}}},{"createdAt":1709695680000,"insightId":"f87a083b-71c6-4bb2-95c3-e0faa4a5f731","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7170386038463422465,7170983553910890496)","threadUrn":"urn:li:ugcPost:7170386038463422465","reactionsCount":0,"commentsCount":1,"canComment":true},"commentary":{"attributes":[],"text":"Congratulations Sissi, excited for your new role!"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7170386038463422465"}}},{"createdAt":1709695620000,"insightId":"49c31045-ad84-4f1c-8764-19d99d149acb","activityUnion":{"commentActivity":{"socialMetadata":{"reactionTypeCounts":[{"type":"LIKE","count":1}],"entityUrn":"urn:li:fs_salesSocialMetadata:urn:li:comment:(ugcPost:7170564139981979648,7170983263107317761)","threadUrn":"urn:li:ugcPost:7170564139981979648","reactionsCount":1,"commentsCount":0,"canComment":true},"commentary":{"attributes":[],"text":"Congratulations Ron! \n"},"activityUrl":"https:\/\/www.linkedin.com\/feed\/sales-navigator\/urn:li:ugcPost:7170564139981979648"}}}]}